<DOC>
	<DOCNO>NCT00568516</DOCNO>
	<brief_summary>To assess effect ASP3550 maintenance serum testosterone suppression patient prostate cancer</brief_summary>
	<brief_title>Phase II Study ASP3550 Patients With Prostate Cancer</brief_title>
	<detailed_description>Two dos ASP3550 administer patient prostate cancer . The primary efficacy variable effect ASP3550 maintenance serum testosterone suppression . In addition , safety pharmacokinetics ASP3550 investigate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Is male patient histologically proven prostate cancer ( adenocarcinoma ) stag Is patient endocrine treatment indicate . Patients rise serum PSA prostatectomy radiotherapy perform curative intention may include Has serum testosterone level 1.5 ng/mL screening Has ECOG ( Eastern Cooperative Oncology Group ) P.S . ( Performance Status ) score 0 2 Previous present endocrine treatment prostate cancer . However , patient undergo neoadjuvant/adjuvant endocrine therapy maximal duration 6 month prostatectomy radiotherapy terminate least 6 month precede Screening Visit may include Is treat 5Î±reductase inhibitor Is candidate curative therapy , i.e. , radical prostatectomy radiotherapy within 12 month Has concurrent history severe asthma ( defined need daily treatment inhalation steroid ) , anaphylactic reaction , severe urticaria angioedema</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ASP3550</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostatic neoplasm</keyword>
</DOC>